Allscripts Acquires ZappRx for Undisclosed Amount

Allscripts’ payer and life sciences business unit is focused on specialty prescribing.

Allscripts acquired ZappRx, a startup focused on modernizing how patients access prescription medicines, according to a spokesperson for the electronic health record (EHR) company.

The Allscripts spokesperson declined to share details of the agreement in an email to Inside Digital Health™.

ZappRx is a Boston-based digital health company that offers a prescription and prior authorization platform to increase efficiencies in how specialty medications reach patients.

Zoe Barry, CEO and co-founder of ZappRx, transitioned from a career on Wall Street to healthcare when her youngest brother was diagnosed with severe epilepsy.

Since its inception in 2012, ZappRx raised an estimated $42 million from investors including Qiming U.S. Healthcare Fund, SR One and GV.

An Allscripts spokesperson said the specialty-prescribing space is a key focus area for its payer and life sciences business unit, Veradigm.

Veradigm is an integrated data systems and services company that delivers data-driven insights to improve the efficiency, value and quality of healthcare delivery. It focuses on increasing value by leveraging data and analytics. Allscripts designed the Veradigm portfolio to optimize the experience and return on investment for clients and patients.

The life sciences unit offers ePrescribe to help stakeholders looking for advanced, affordable electronic prescribing or a health information technology company looking to integrate an electronic prescribing solution into its platform.

“Allscripts is excited to add ZappRx’s platform to our growing portfolio,” the spokesperson wrote.

Get the best insights in digital health directly to your inbox.

Related

Allscripts Sells $525M Netsmart Stake to Private Equity Firms

Has Health IT Adoption Improved Patient Outcomes?

Why C-Suites Need to Get a Grip on Physician Burnout